ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
6 announcements with these filters
Orchid Pharma's Q1FY27 revenue grew 15% YoY to INR 304Cr, with EBITDA rising to INR 25Cr. The company is pivoting toward complex, high-value molecules and backward integration.
Management reports a recovery in Q1 FY27 with 15% revenue growth after a difficult FY26, but remains cautious due to industry-wide overcapacity and pricing pressure.
Orchid Pharma reported strong Q1FY27 performance following the strategic amalgamation of Dhanuka Laboratories, transforming into an integrated cephalosporin platform with a significant turnaround in profitability metrics.
Orchid Pharma reports FY26 standalone revenue of ₹811cr and EBITDA of ₹101cr. Strategy shifts towards platform creation, including the Dhanuka merger and entering the U.S. sterile formulation market.
Orchid Pharma is pivoting from a recovery phase to a higher-margin 'platform creation' model, integrating Dhanuka Laboratories and aggressively targeting the US sterile cephalosporin market.
Orchid Pharma reports FY26 standalone revenue of ₹811 Cr and PAT of ₹45 Cr, focusing on transitioning from a turnaround to an integrated cephalosporin platform with major capex in 7ACA.